Your browser doesn't support javascript.
loading
Exposure-response analyses of BRAF- and MEK-inhibitors dabrafenib plus trametinib in melanoma patients.
Groenland, Stefanie L; Janssen, J M; Nijenhuis, C M; de Vries, N; Rosing, H; Wilgenhof, S; van Thienen, J V; Haanen, J B A G; Blank, C U; Beijnen, J H; Huitema, A D R; Steeghs, N.
Afiliación
  • Groenland SL; Division of Medical Oncology, Department of Clinical Pharmacology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands. s.groenland@nki.nl.
  • Janssen JM; Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Nijenhuis CM; Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • de Vries N; Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Rosing H; Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Wilgenhof S; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • van Thienen JV; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Haanen JBAG; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Blank CU; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Beijnen JH; Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Huitema ADR; Department of Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.
  • Steeghs N; Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Cancer Chemother Pharmacol ; 91(6): 447-456, 2023 06.
Article en En | MEDLINE | ID: mdl-36947208
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Cutáneas / Melanoma Tipo de estudio: Observational_studies Límite: Humans Idioma: En Revista: Cancer Chemother Pharmacol Año: 2023 Tipo del documento: Article País de afiliación: Países Bajos Pais de publicación: Alemania
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Cutáneas / Melanoma Tipo de estudio: Observational_studies Límite: Humans Idioma: En Revista: Cancer Chemother Pharmacol Año: 2023 Tipo del documento: Article País de afiliación: Países Bajos Pais de publicación: Alemania